STCube, AACR Abstract Released

[Asia Economy Reporter Hyungsoo Park] STCube, a developer of immune checkpoint inhibitors, announced on the 15th that it has released abstracts for two research outcomes of ‘hSTC810’ to be presented next month at the American Association for Cancer Research (AACR).

The presentations will cover the determination of the starting dose of hSTC810, the world’s first antibody targeting the novel immune therapy target BTN1A1, and its synergistic effects with radiation therapy (RT).

hSTC810 is under development to evaluate its safety profile and confirm an effective dose as an anticancer agent through clinical trials. It received approval for a Phase 1 clinical trial from the U.S. Food and Drug Administration (FDA) in January and is currently preparing to enroll the first patient.

The first topic will present simulation results for starting doses to determine the initial administration concentration. After intravenous (IV) administration in humans, the pharmacokinetic profile of hSTC810 was predicted, and the starting dose was set based on a minimum anticipated biological effect level (MABEL) corresponding to 20% receptor occupancy (RO).

An STCube official stated, "Setting the dose for the first patient is a critical aspect from a toxicological perspective," and added, "The starting dose was determined using the receptor occupancy (RO) method."

A company representative said, "We tested the combined effect of radiation exposure and the anti-BTN1A1 antibody through animal studies," and confirmed, "The combination of RT and the anti-BTN1A1 antibody resulted in enhanced antitumor effects."

They continued, "hSTC810 is a new immune checkpoint inhibitor for patients who do not respond to existing immunotherapies such as PD-1 and PD-L1 treatments," and expressed expectations that "meaningful results will continue to be derived through clinical trials."

This content was produced with the assistance of AI translation services.